Tumori Journal Abstract Book - October 2020 - 202

202
Background: Immune ceck-point inhibitors (CKi) are
playing a central role in the management of many cancers.
The experiences of patients and physicians in routine clinical practice is often different from those in trial setting.
This study presents data from a group of consecutive
patients in real world setting.
Material and Methods: From 2018 to 2020 all consecutive
patients with indication of CKi therapy were enrolled. We
record age, PS, PDL-1 expression, smoking status, site of
cancer, treatment planning, response, toxicity and survival.
Results: Fifty-two patients were enrolled, 43 NSCLC (32
ADK + 12 SQM) 5 Kidney, 2 bladder and 2 breast cancers,
Median Age was 68 y. (range 41-83), 38 Male and 14
Female, no smokers were only 10%, PDL-1 score was
1-49% in 20 pts and negative or unknown in other 32,
ECOG score was 0-1 in 44 pts and 2 in 8 pts. Four pts present second synchronous tumors (2 Colon, 1 HCC, 1
Pancreas), and 2 pts suffered by HIV infection. N/L ratio >
3 is present in 13 pts and LDH over normal values in 14 pts.
Nivolumab was administered in 27 pts, Pembrolizumab
in17 pts and Atezolizumab in 8 pts, while 20 pts, 8 with
brain lesions, underwent palliative RT. Duration of treatment was < 6 m in 18 pts, 6-12 m in 24 pts, 12-24 m in 5
pts and > 24 min 5 pts. Recist' evaluation after 3 months of
therapy revealed 13 PR+ 20 SD+ 19 PD with a DCR of
63%. In the NSCLC the DCR is 27/43; 80% in 20 PDL-1
positive pts and 49% in 23 negative ones. Overall Survival
at 12 m. is 41%; OS at 24 m. is 23%. Treatment continued
beyond progression in 4 pts because clinical benefit.
Adverse Effects of any grade were reported in 20 pts (39%),
while in six pts (12%) G3/4 AE as pneumonia, mucositis,
muscle pain, adrenal failure and iper PD were responsible
to stop therapy, 5/6 AE occourred in Nivolumab pts.
Conclusions: Our data confirm the efficacy of CKi in the
management of advanced cancers, specially in NSCLC
when PDL-1 score is present (DCR 80%), but we record a
worse toxicity (12%) than expected from clinical trial.

Tumori Journal 106(2S)
impact on the quality of life of cancer patients, regardless
of gender and age, but women are most affected; it is experienced as a decrease in beauty and sensuality and induces
a change in one's body image. It is also experienced as a
continuous demonstration of one's illness, altering social
relationships; this physical and emotional problem can
also lead to less adherence to chemotherapy treatments.
Scalp cooling with the use of the Paxman scalp cooling
device system has proven to be effective in preventing or
reducing this problem, reporting success rates of around
60%. We present the preliminary data of the first 4 months
of use of this device at the 3 ASReM Oncology Centers in
our region.
Patients and methods: Between January and April 35
women were treated (30 with breast cancer, 5 with gynecological cancer), with an average age of 57 years. CTCA
version 5.0 was used to evaluate the results in terms of hair
loss. All patients are treated with polychemotherapy regimens containing anthracyclines and / or taxanes.
Results: 7 patients (20%) stopped treatment for intolerance (5) or headache (2). Of the 28 evaluable patients, all
still on treatment, 4 (11%) are not yet evaluable because
they have just started treatment, 1 had G2 toxicity (3%), 23
(66%) an alopecia G0 or G1. At the moment, all patients
treated with Paxman scalp cooling device are satisfied
with the presence in terms of tolerability. The most frequently reported side effects were the feeling of cold and
migraine. The results we obtained are in line with the studies published so far and patient satisfaction supports the
usefulness of the Paxman device to prevent hair loss during chemotherapy. Maintaining the low temperature before
and after chemotherapy forces patients to stay longer in the
ward (about 2 hours, depending on the scheme used), representing a limit to the use of the device.
Conclusions: The use of Paxman equipment represents in
any case an added value offered by our departments in
order to improve the quality of life of our patients thus
promoting the maintenance of normal social relationships

T51
Preliminary data on the use of
Paxman scalp cooling device
to prevent alopecia from
chemotherapy in ASReM oncology
centers
Calista F.1, Musacchio M.1, Specchia M.1, Traficante D.2, Carrozza
F.3, Assalone P.2, Tomei F.2, Domenica D.3, Piscopo A.1, Cefalogli C.2,
Farina P.3, Giglio G.1
1
Azienda Sanitaria Regionale del Molise - UOC Oncologia Campobasso,
Campobasso; 2Azienda Sanitaria Regionale del Molise - UOS Oncologia
Isernia, Isernia; 3Azienda Sanitaria Regionale del Molise - UOS Oncologia
Termoli, Termoli

Background: Alopecia is one of the most common side
effects caused by chemotherapy. It has a strongly negative

T52
Denosumab (DMAB) and
Osteonecrosis of the jaw (ONJ)
Belloni P.1, Pelliccioni M.1, Toniolo D.1, Candido P.1, Cozzi C.1, Bollina R.1
1

ASST-Rhodense- UO di Oncologia Medica, Rho, Milano

Osteonecrosis of the jaw (ONJ) is characterized by unexpected appearance of necrotic bone in the jaw (70%), the
maxilla (30%) or other bone (10%). This condition occurs
in cancer patients receveing biphosphonates (BP) or
Denosumab (DMAB) for bone metastatic lesions.
Predisposing factors for this adverse event include cancer
condition and cancer comedications (chemotherapy, steroids, hand and neck irradiation). An interdisciplinary team

Tumori Journal Abstract Book - October 2020

Table of Contents for the Digital Edition of Tumori Journal Abstract Book - October 2020